BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30359249)

  • 61. Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study.
    Shim SH; Lim MC; Lee D; Won YJ; Ha HI; Chang HK; Cho H
    J Gynecol Oncol; 2022 Jan; 33(1):e5. PubMed ID: 34783208
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP
    Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Breast cancer following ovarian cancer in BRCA mutation carriers.
    Gangi A; Cass I; Paik D; Barmparas G; Karlan B; Dang C; Li A; Walsh C; Rimel BJ; Amersi FF
    JAMA Surg; 2014 Dec; 149(12):1306-13. PubMed ID: 25372568
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
    Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry.
    Stenzel AE; Buas MF; Moysich KB
    Cancer Epidemiol; 2019 Oct; 62():101580. PubMed ID: 31400533
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A prognostic system for epithelial ovarian carcinomas using machine learning.
    Grimley PM; Liu Z; Darcy KM; Hueman MT; Wang H; Sheng L; Henson DE; Chen D
    Acta Obstet Gynecol Scand; 2021 Aug; 100(8):1511-1519. PubMed ID: 33665831
    [TBL] [Abstract][Full Text] [Related]  

  • 68. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 72. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
    Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
    Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Screening for
    Al-Qahtani WS; Alduwish MA; Al-Olayan EM; Aljarba NH; Em AH; Albani FG; Domiaty DM; Al-Otaibi AM; Qattan SMA; Almurshedi AS; Elasbali AM; Ahmed HG; Almutlaq BA
    J Obstet Gynaecol; 2021 Oct; 41(7):1127-1133. PubMed ID: 33475035
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
    Kim J; Chang Y; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    J Gynecol Oncol; 2019 Jan; 30(1):e11. PubMed ID: 30479095
    [TBL] [Abstract][Full Text] [Related]  

  • 77. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 78. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Falconer H; Joneborg U; Krawiec K; Palsdottir K; Bottai M; Salehi S
    Gynecol Oncol; 2020 Oct; 159(1):58-65. PubMed ID: 32712154
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Le Saux O; Decullier E; Freyer G; Glehen O; Bakrin N
    Int J Hyperthermia; 2018; 35(1):652-657. PubMed ID: 30295114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.